The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).
S. Stacchiotti
Honoraria - Pfizer
Research Funding - Pfizer
P. Verderio
No relevant relationships to disclose
A. Messina
Honoraria - Pfizer
Research Funding - Pfizer
C. Morosi
Honoraria - Pfizer
Research Funding - Pfizer
A. Ferraro
No relevant relationships to disclose
V. Quagliuolo
No relevant relationships to disclose
J. Martin
No relevant relationships to disclose
A. Comandone
Honoraria - Pfizer
G. Grignani
No relevant relationships to disclose
P. Picci
No relevant relationships to disclose
S. Frustaci
Honoraria - Pfizer
A. Gronchi
Honoraria - Pfizer
P. G. Casali
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer